BR112017011798A2 - 4,6-substituído-pirazolo[1,5-a] pirazinas como inibidores janus cinase - Google Patents

4,6-substituído-pirazolo[1,5-a] pirazinas como inibidores janus cinase

Info

Publication number
BR112017011798A2
BR112017011798A2 BR112017011798A BR112017011798A BR112017011798A2 BR 112017011798 A2 BR112017011798 A2 BR 112017011798A2 BR 112017011798 A BR112017011798 A BR 112017011798A BR 112017011798 A BR112017011798 A BR 112017011798A BR 112017011798 A2 BR112017011798 A2 BR 112017011798A2
Authority
BR
Brazil
Prior art keywords
pyrazines
pyrazolo
substituted
kinase inhibitors
janus kinase
Prior art date
Application number
BR112017011798A
Other languages
English (en)
Inventor
L Bennett Brydon
F Kraser Christopher
Laird Ellen
James Hicken Erik
Bradford Fell Jay
Pheneger Jed
e robinson John
Gaudino John
P Fischer John
Leftheris Katerina
E Burgess Laurence
J Chicarelli Mark
Laurence Boys Mark
K Raheja Raj
Andrew RIEGER Robert
Jay Hinklin Ronald
Allen Shelley
p tang Tony
Satoh Yoshitaka
Original Assignee
Array Biopharma Inc
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc, Celgene Corp filed Critical Array Biopharma Inc
Publication of BR112017011798A2 publication Critical patent/BR112017011798A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Abstract

a presente invenção refere-se a compostos de fórmula i: e estereoisômeros e sais e solvatos farmaceuticamente aceitáveis dos mesmos em que r1, r2, r3 e r4 têm os mesmos significados apresentados na especificação, são inibidores de uma ou mais jak cinases e são úteis no tratamento de distúrbios e doenças associados com jak cinase, como doenças autoimunes, doenças inflamatórias, rejeição de órgãos, tecidos e células transplantados, bem como distúrbios e malignidades hematológicas e suas comorbidades.
BR112017011798A 2014-12-05 2015-12-04 4,6-substituído-pirazolo[1,5-a] pirazinas como inibidores janus cinase BR112017011798A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462088068P 2014-12-05 2014-12-05
PCT/US2015/064062 WO2016090285A1 (en) 2014-12-05 2015-12-04 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
BR112017011798A2 true BR112017011798A2 (pt) 2017-12-26

Family

ID=55069089

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011798A BR112017011798A2 (pt) 2014-12-05 2015-12-04 4,6-substituído-pirazolo[1,5-a] pirazinas como inibidores janus cinase

Country Status (29)

Country Link
US (3) US10189845B2 (pt)
EP (2) EP3878451A1 (pt)
JP (2) JP6641373B2 (pt)
KR (1) KR20170090476A (pt)
CN (1) CN107278203B (pt)
AU (1) AU2015357585B2 (pt)
BR (1) BR112017011798A2 (pt)
CA (1) CA2969709A1 (pt)
CL (1) CL2017001422A1 (pt)
CO (1) CO2017006674A2 (pt)
CR (1) CR20170309A (pt)
DK (1) DK3227297T3 (pt)
ES (1) ES2865483T3 (pt)
HR (1) HRP20210501T1 (pt)
HU (1) HUE054371T2 (pt)
IL (1) IL252656A0 (pt)
MX (1) MX2017007284A (pt)
MY (1) MY191016A (pt)
PH (1) PH12017501032A1 (pt)
PL (1) PL3227297T3 (pt)
PT (1) PT3227297T (pt)
RS (1) RS61693B1 (pt)
RU (2) RU2742938C2 (pt)
SG (1) SG11201704542SA (pt)
SI (1) SI3227297T1 (pt)
TW (1) TWI725004B (pt)
UA (1) UA120065C2 (pt)
WO (1) WO2016090285A1 (pt)
ZA (1) ZA201704494B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170309A (es) 2014-12-05 2018-02-02 Celgene Corp Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas
CO2018008799A2 (es) * 2016-02-24 2018-09-20 Pfizer Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de jak
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
KR20230107407A (ko) 2016-06-16 2023-07-14 데날리 테라퓨틱스 인크. 신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서피리미딘-2-일아미노-1h-피라졸
GB201617758D0 (en) * 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
WO2018217946A1 (en) * 2017-05-24 2018-11-29 Denali Therapeutics Inc. Compounds, compositions and methods
US11254668B2 (en) 2017-08-14 2022-02-22 Pfizer Inc. Pyrazolo[1,5-A]pyrazin-4-yl and related derivatives
TWI802635B (zh) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
TW201932464A (zh) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
JP7256291B2 (ja) * 2019-04-12 2023-04-11 プライムジーン(ベイジン)カンパニー リミテッド ピラゾロピラジン誘導の化合物、医薬組成物およびその使用
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN113150012B (zh) * 2020-01-22 2023-03-24 浙江海正药业股份有限公司 吡唑并[1,5-a]吡嗪类衍生物及其制备方法和用途
CA3177852A1 (en) 2020-04-04 2021-10-07 Pfizer Inc. Methods of treating coronavirus disease 2019
WO2023083200A1 (zh) * 2021-11-12 2023-05-19 南京明德新药研发有限公司 吡唑并环化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010981A1 (en) 1998-08-21 2000-03-02 Parker Hughes Institute Quinazoline derivatives
DE102007032349A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
ME02186B (me) * 2009-12-23 2016-02-20 Takeda Pharmaceuticals Co Fuzionisani heteroaromatski pirolidinoni kao syk inhibitori
WO2011089400A1 (en) * 2010-01-22 2011-07-28 Centro Nacional De Investigaciones Oncológicas (Cnio) Inhibitors of pi3 kinase
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
US20110241987A1 (en) * 2010-04-01 2011-10-06 Smart Technologies Ulc Interactive input system and information input method therefor
KR20130094710A (ko) 2010-04-14 2013-08-26 어레이 바이오파마 인크. Jak 키나아제의 억제제로서 5,7-치환된-이미다조[1,2-c]피리미딘
KR20140076619A (ko) * 2011-10-12 2014-06-20 어레이 바이오파마 인크. 5,7-치환된-이미다조[1,2-c]피리미딘
CN104169284B (zh) * 2012-03-28 2017-03-29 默克专利股份公司 双环吡嗪酮衍生物
CR20170309A (es) 2014-12-05 2018-02-02 Celgene Corp Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas

Also Published As

Publication number Publication date
RU2021102805A (ru) 2021-02-12
US20200291039A1 (en) 2020-09-17
CO2017006674A2 (es) 2017-10-20
EP3878451A1 (en) 2021-09-15
DK3227297T3 (da) 2021-04-06
JP2020055859A (ja) 2020-04-09
EP3227297A1 (en) 2017-10-11
AU2015357585B2 (en) 2020-07-02
RU2742938C2 (ru) 2021-02-11
US11028093B2 (en) 2021-06-08
CL2017001422A1 (es) 2018-01-05
ES2865483T3 (es) 2021-10-15
US20190177328A1 (en) 2019-06-13
RU2017123387A3 (pt) 2019-06-03
CN107278203B (zh) 2020-05-19
RU2017123387A (ru) 2019-01-11
PL3227297T3 (pl) 2021-10-25
US20170362240A1 (en) 2017-12-21
ZA201704494B (en) 2022-03-30
UA120065C2 (uk) 2019-09-25
US10730880B2 (en) 2020-08-04
CN107278203A (zh) 2017-10-20
PT3227297T (pt) 2021-04-09
HUE054371T2 (hu) 2021-09-28
CR20170309A (es) 2018-02-02
SI3227297T1 (sl) 2021-04-30
EP3227297B1 (en) 2021-01-20
RS61693B1 (sr) 2021-05-31
KR20170090476A (ko) 2017-08-07
US10189845B2 (en) 2019-01-29
TW201632523A (zh) 2016-09-16
IL252656A0 (en) 2017-07-31
WO2016090285A1 (en) 2016-06-09
JP2018507167A (ja) 2018-03-15
TWI725004B (zh) 2021-04-21
MY191016A (en) 2022-05-28
HRP20210501T1 (hr) 2021-05-14
AU2015357585A1 (en) 2017-07-13
SG11201704542SA (en) 2017-07-28
CA2969709A1 (en) 2016-06-09
PH12017501032A1 (en) 2017-11-27
JP6641373B2 (ja) 2020-02-05
MX2017007284A (es) 2017-08-25

Similar Documents

Publication Publication Date Title
BR112017011798A2 (pt) 4,6-substituído-pirazolo[1,5-a] pirazinas como inibidores janus cinase
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
ECSP16054826A (es) Derivados Novedosos de Amino Pirimidina
BR112014008865A2 (pt) imidazo[1,2-c]pirimidinas 5,7-substituídas
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
BR112012020693A2 (pt) derivados de ciclobutano e metilciclobutano como inibidores de janus quinase
CO6630187A2 (es) 5.7-sustituido -imidazol[1.2-c]pirimidinas como inhibidores de cinasas jak
BR112015009942A2 (pt) derivados de tiofeno fundidos tricíclicos como inibidores de jak
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
MX2020006614A (es) Derivados de cromenopiridina como inhibidores de fosfatidilinositol fosfato cinasa,.
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
MX2018011283A (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer.
BR112015023078A2 (pt) inibidores de pirrolopirimindina cdk9 quinase
BR112018007720A2 (pt) novos derivados de piridona e seu uso como inibidores da quinase
BR112017023121A2 (pt) composto, composição farmacêutica, processo para a preparação de uma composição, método de tratamento do câncer, kit para o tratamento terapêutico do câncer e uso de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2751 DE 26/09/2023.